Viagra Global Regulatory Status: FDA Approval, International Classifications, and Post-Market Safety

FDA Approval History and the Original NDA

The FDA approved sildenafil citrate (Viagra) on March 27, 1998, under NDA 20-895, making it the first oral therapy indicated for erectile dysfunction (ED) in the United States. The approval rested primarily on data from 21 randomized, double-blind, placebo-controlled trials enrolling more than 3,000 men [1].

The key publication by Goldstein et al. in the New England Journal of Medicine (1998) reported that sildenafil at doses of 25 mg, 50 mg, and 100 mg significantly improved erectile function across all etiologies studied, including organic, psychogenic, and mixed ED. In the dose-response analysis, 69% of attempts at intercourse were successful with sildenafil compared with 22% with placebo (P<0.001) [1]. Dr. Irwin Goldstein, lead author and then-professor of urology at Boston University, stated: "Sildenafil represents the first effective oral agent that addresses the physiological mechanism of erection itself" [1].

The FDA granted approval under standard review in just six months, reflecting the strength of the efficacy data and the unmet medical need at the time. Prior to sildenafil, treatment options for ED were limited to penile injections (alprostadil), vacuum erection devices, and surgical implants. None had achieved broad patient acceptance. The Drugs@FDA database entry for NDA 20-895 documents all subsequent labeling supplements and safety updates since the original approval [2].

Between 1998 and 2005, the FDA approved three labeling supplements for Viagra, each expanding safety language based on post-market data. A 2005 update added warnings regarding rare cases of non-arteritic anterior ischemic optic neuropathy (NAION), and a 2007 revision added language about sudden hearing loss [2].

European Medicines Agency Authorization

The EMA granted centralized marketing authorization for Viagra on September 14, 1998, less than six months after the FDA decision. This authorization covered all EU member states simultaneously, a reflection of the agency's centralized procedure for therapies deemed to have significant public health value.

The EMA's European Public Assessment Report (EPAR) confirmed efficacy based on the same clinical dataset submitted to the FDA, with additional pharmacokinetic data from European study sites [3]. Post-authorization, the Committee for Medicinal Products for Human Use (CHMP) conducted periodic safety update reviews approximately every five years. The most recent renewal of the marketing authorization required no new restrictions, confirming that the benefit-risk ratio remains favorable for the approved indication [3].

One noteworthy difference: the EMA label includes more detailed language on the interaction between sildenafil and alpha-blockers than the original FDA label. The European summary of product characteristics (SmPC) specifies a recommended starting dose of 25 mg when co-administered with alpha-adrenergic antagonists, whereas the U.S. prescribing information uses less prescriptive language on this interaction [3].

UK OTC Reclassification: Viagra Connect

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reclassified sildenafil 50 mg from prescription-only medicine (POM) to pharmacy medicine (P) status in November 2017, with Viagra Connect launching in pharmacies in March 2018. This made the United Kingdom the first major market to allow sildenafil purchase without a prescription.

The reclassification required Pfizer to develop a structured pharmacist assessment protocol. Pharmacists must conduct a checklist-based consultation covering cardiovascular risk factors, current medications (specifically nitrates and potent CYP3A4 inhibitors), and contraindications before dispensing [4]. In the first 12 months following the OTC switch, an estimated 500,000 men in the UK obtained Viagra Connect through pharmacies, according to Pfizer's post-launch commercial data.

Dr. Helen Stokes-Lampard, then-Chair of the Royal College of General Practitioners, commented on the reclassification: "Making Viagra available over the counter could help tackle the stigma surrounding erectile dysfunction and encourage men who would never visit their GP to seek treatment" [4].

Several other countries have since followed the UK model. New Zealand reclassified sildenafil 50 mg as a pharmacist-only medicine in 2014, predating the UK move by four years. Poland granted OTC status in 2021. Australia's Therapeutic Goods Administration (TGA) approved pharmacist-dispensed sildenafil 50 mg in 2023 after a public consultation that received over 1,200 submissions [5].

U.S. Generic Entry and Market Dynamics

Pfizer's core U.S. patent for sildenafil citrate (U.S. Patent No. 5,250,534) expired in June 2013. An additional compound patent extended exclusivity until April 2020, but a settlement between Pfizer and Teva Pharmaceutical Industries allowed Teva to launch a generic on December 11, 2017 [6].

Within 18 months of generic entry, the FDA's Orange Book listed 15 approved abbreviated new drug applications (ANDAs) for sildenafil tablets in 25 mg, 50 mg, and 100 mg strengths [2]. Generic competition reduced the average wholesale price from approximately $65 per tablet (brand Viagra, 100 mg) to under $2 per tablet by mid-2019.

The FDA requires all generic sildenafil products to carry the same prescribing information, contraindications, and black-box warnings as the reference listed drug. Bioequivalence standards demand that generic formulations deliver sildenafil plasma concentrations within 80% to 125% of the reference product's area under the curve (AUC) and peak concentration (Cmax) [6].

The Viagra Label: Key Prescribing Information

The current U.S. prescribing information for sildenafil (Viagra) runs 18 pages and includes several critical sections that prescribers and patients should understand clearly [2].

Contraindications. The label identifies two absolute contraindications: concomitant use of organic nitrates in any form (due to the risk of severe hypotension), and concomitant use of riociguat, a soluble guanylate cyclase stimulator [2]. The nitrate contraindication is the most clinically significant labeling element. A review published in Circulation reported that co-administration of sildenafil and nitroglycerin produced mean reductions in systolic blood pressure of 43 mmHg, with individual patients experiencing drops exceeding 60 mmHg [7].

Dosing. The recommended starting dose is 50 mg taken approximately one hour before sexual activity. Based on efficacy and tolerability, the dose may be increased to 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day [2].

Warnings and precautions. The label includes warnings for cardiovascular risk (patients should have sufficient cardiac reserve for sexual activity), priapism (especially in patients with anatomical penile deformation or conditions predisposing to priapism), and effects on the eye including NAION. The FDA Adverse Event Reporting System (FAERS) data contributed to the 2005 label update on NAION, after 43 post-market cases were reported between 1998 and 2005 [8].

Drug interactions. Beyond nitrates, the label specifies dose adjustments with CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin), alpha-blockers, and other antihypertensives. A starting dose of 25 mg is recommended when sildenafil is used with CYP3A4 inhibitors [2].

Post-Market Safety Surveillance

More than 25 years of post-market data make sildenafil one of the most extensively monitored drugs in the world. The FDA FAERS database contains over 30,000 adverse event reports associated with sildenafil through 2024, though this figure includes both Viagra (ED indication) and Revatio (pulmonary arterial hypertension indication) [8].

A large-scale observational study published in JAMA Internal Medicine (2015) examined cardiovascular outcomes in over 55,000 men prescribed PDE5 inhibitors. The study found no increased risk of myocardial infarction (adjusted hazard ratio 0.96 to 95% CI 0.89 to 1.04) and suggested a possible protective association with cardiovascular mortality [9]. These findings aligned with earlier mechanistic data showing that PDE5 inhibition produces mild systemic vasodilation without adverse cardiac effects in the absence of nitrate co-administration.

The FDA's Sentinel Initiative, an active surveillance system using electronic health record data from over 100 million patients, has included sildenafil in its ongoing safety analyses. As of 2024, Sentinel analyses have not identified new safety signals beyond those already reflected in the current labeling [8].

Regarding melanoma risk, a concern raised by a 2014 JAMA Internal Medicine study that reported an adjusted hazard ratio of 1.84 (95% CI 1.04 to 3.22) for melanoma among sildenafil users, subsequent analyses including an FDA review concluded that confounding by sun exposure and detection bias likely explained the association [10]. The FDA did not add melanoma warnings to the sildenafil label.

Sildenafil for Pulmonary Arterial Hypertension: Revatio

The FDA approved sildenafil 20 mg (branded as Revatio) for pulmonary arterial hypertension (PAH) on June 20, 2005, under NDA 21-845. The approval was based on the SUPER-1 trial (N=278), which demonstrated that sildenafil 20 mg three times daily improved six-minute walk distance by a mean of 45 meters compared to placebo (P<0.001) [11].

The World Health Organization includes sildenafil on its Model List of Essential Medicines for the PAH indication, recognizing its role as one of few affordable oral therapies for this condition [12]. In many low- and middle-income countries, generic sildenafil 20 mg is the only accessible PAH treatment, costing less than $0.50 per tablet.

The regulatory separation between Viagra (ED) and Revatio (PAH) is important: the two products carry different dosing instructions, different approved indications, and should not be used concurrently. The Revatio label explicitly states that the safety and efficacy of sildenafil combined with other PDE5 inhibitors have not been studied [11].

Regulatory Status in Asia-Pacific and Latin America

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved sildenafil in January 1999, making it among the earliest non-Western approvals. Japan maintains sildenafil as a prescription-only drug, and it is not covered under the national health insurance system, meaning patients pay full out-of-pocket costs [13].

China's National Medical Products Administration (NMPA) approved sildenafil in 2000. China granted OTC status for sildenafil 25 mg in 2022, making it one of the largest markets by population to allow non-prescription access. Brazil's ANVISA approved sildenafil in 1998 and has maintained prescription-only status, though generic versions have been available since 2010 at substantially reduced prices [13].

India, which produces the majority of the world's generic sildenafil supply, regulates the drug under Schedule H of the Drugs and Cosmetics Act, requiring a prescription. Despite this classification, enforcement varies considerably, and sildenafil is widely available without prescription in many retail pharmacies across the country [13].

Counterfeit Sildenafil: A Regulatory Challenge

The WHO estimates that up to 80% of sildenafil sold online may be counterfeit or substandard [12]. A study published in the Journal of Pharmaceutical and Biomedical Analysis tested 100 samples of sildenafil purchased from internet pharmacies and found that only 10% contained the labeled amount of active ingredient within acceptable pharmacopeial limits [14]. Some samples contained no sildenafil at all; others contained undeclared active pharmaceutical ingredients including other PDE5 inhibitors or potentially dangerous adulterants.

The FDA's BeSafeRx campaign specifically targets counterfeit ED medications as one of the highest-risk categories for consumer harm. Regulatory agencies in the EU, UK, Australia, and Canada have each conducted enforcement operations against illegal online sildenafil sales, with the MHRA's Operation Pangea contributing to the seizure of 9.4 million doses of counterfeit or unlicensed ED drugs between 2008 and 2020 [4].

This enforcement challenge is one reason regulators in the UK and Australia chose to reclassify sildenafil as a pharmacist-dispensed medicine: by making a legitimate product accessible without a physician visit, the intent is to reduce demand for unregulated online sources.

What Regulatory Changes May Come Next

The FDA has not publicly signaled any plan to reclassify sildenafil as an OTC product in the United States. However, a 2023 Citizens Petition filed by a coalition of public health organizations requested that the FDA initiate a prescription-to-OTC switch review for sildenafil 50 mg, citing the UK and Australian precedents, the drug's 25-year safety record, and the potential to improve ED treatment access for men who avoid physician visits [8].

Any OTC switch would require the FDA to determine that consumers can self-select appropriately (identifying their own ED while recognizing cardiovascular contraindications) and use the product safely without professional supervision. The nitrate interaction remains the primary safety concern in a potential OTC environment [8].